Cargando…
OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
Introduction: Teprotumumab, an insulin-like growth factor 1 receptor inhibitory monoclonal antibody, was recently shown to significantly reduce proptosis in patients with active, moderate-to-severe thyroid eye disease (TED) in phase 2 and phase 3 clinical trials.(1,2) Prior analyses have demonstrate...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208043/ http://dx.doi.org/10.1210/jendso/bvaa046.1103 |